The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 10 Apr 2018
At a glance
- Drugs Apalutamide (Primary) ; LHRH receptor agonists
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Aragon Pharmaceuticals; Johnson & Johnson
- 31 Aug 2018 Biomarkers information updated
- 06 Apr 2018 Planned End Date changed from 31 Jan 2020 to 31 Dec 2019.
- 06 Apr 2018 Planned primary completion date changed from 31 Jan 2019 to 31 Dec 2019.